AbCellera reported positive Phase 2 top-line results for ABCL-635, an injectable neurokinin-3 receptor antagonist for menopausal vasomotor symptoms. In a randomized, double-blind, placebo-controlled Phase 2 portion enrolling 92 postmenopausal women, a single 600 mg subcutaneous dose met primary efficacy endpoints at week 4. The company said ABCL-635 significantly reduced both frequency and severity of moderate-to-severe hot flashes versus placebo and also improved sleep and patient global impression of change. AbCellera positioned the data as a new efficacy benchmark that could inform Phase 3 design. For biotech investors, the readout matters as non-hormonal, long-acting options compete for share in a market where durability and tolerability can drive rapid uptake.